Home Machinery & Equipment Industrial Equipment Nifedipine Market

Nifedipine Market Size, Share & Trends Analysis Report By Type (Nifedipine Controlled-Release Tablets, Nifedipine Extended Action Tablets), By Application (Primary Pulmonary Hypertension, Heart Failure, Raynaud’s Syndrome, Cephalalgia, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), By Region (North America, Asia-Pacific, Europe, Latin America, The Middle East and Africa) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Mitiksha Koul | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Nifedipine Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Nifedipine Controlled-Release Tablets
    2. Nifedipine Extended Action Tablets
  2. Nifedipine Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Primary Pulmonary Hypertension
    2. Heart Failure
    3. Raynaud’s Syndrome
    4. Cephalalgia
    5. Others
  3. Nifedipine Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Retail Pharmacies
    3. Others
  4. Nifedipine Market, By Region 2022-2034 (USD MILLION/ Units)
    1. North America
    2. Asia-Pacific
    3. Europe
    4. Latin America
    5. The Middle East and Africa
  5. Regional Nifedipine Market
    1. North America
      1. North America Nifedipine Market By Type 2022-2034 (USD MILLION/ Units)
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
      2. North America Nifedipine Market By Application 2022-2034 (USD MILLION/ Units)
        1. Primary Pulmonary Hypertension
        2. Heart Failure
        3. Raynaud’s Syndrome
        4. Cephalalgia
        5. Others
      3. North America Nifedipine Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Others
      4. North America Nifedipine Market By Region 2022-2034 (USD MILLION/ Units)
        1. North America
        2. Asia-Pacific
        3. Europe
        4. Latin America
        5. The Middle East and Africa
      5. U.S.
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      6. Canada
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
    2. Europe
      1. Europe Nifedipine Market By Type 2022-2034 (USD MILLION/ Units)
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
      2. Europe Nifedipine Market By Application 2022-2034 (USD MILLION/ Units)
        1. Primary Pulmonary Hypertension
        2. Heart Failure
        3. Raynaud’s Syndrome
        4. Cephalalgia
        5. Others
      3. Europe Nifedipine Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Others
      4. Europe Nifedipine Market By Region 2022-2034 (USD MILLION/ Units)
        1. North America
        2. Asia-Pacific
        3. Europe
        4. Latin America
        5. The Middle East and Africa
      5. U.K.
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      6. Germany
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      7. France
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      8. Spain
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      9. Italy
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      10. Russia
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      11. Nordic
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      12. Benelux
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      13. Rest of Europe
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
    3. APAC
      1. APAC Nifedipine Market By Type 2022-2034 (USD MILLION/ Units)
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
      2. APAC Nifedipine Market By Application 2022-2034 (USD MILLION/ Units)
        1. Primary Pulmonary Hypertension
        2. Heart Failure
        3. Raynaud’s Syndrome
        4. Cephalalgia
        5. Others
      3. APAC Nifedipine Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Others
      4. APAC Nifedipine Market By Region 2022-2034 (USD MILLION/ Units)
        1. North America
        2. Asia-Pacific
        3. Europe
        4. Latin America
        5. The Middle East and Africa
      5. China
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      6. Korea
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      7. Japan
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      8. India
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      9. Australia
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      10. Singapore
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      11. Taiwan
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      12. South East Asia
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      13. Rest of Asia-Pacific
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
    4. Middle East and Africa
      1. Middle East and Africa Nifedipine Market By Type 2022-2034 (USD MILLION/ Units)
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
      2. Middle East and Africa Nifedipine Market By Application 2022-2034 (USD MILLION/ Units)
        1. Primary Pulmonary Hypertension
        2. Heart Failure
        3. Raynaud’s Syndrome
        4. Cephalalgia
        5. Others
      3. Middle East and Africa Nifedipine Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Others
      4. Middle East and Africa Nifedipine Market By Region 2022-2034 (USD MILLION/ Units)
        1. North America
        2. Asia-Pacific
        3. Europe
        4. Latin America
        5. The Middle East and Africa
      5. UAE
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      6. Turkey
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      7. Saudi Arabia
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      8. South Africa
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      9. Egypt
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      10. Nigeria
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      11. Rest of MEA
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
    5. LATAM
      1. LATAM Nifedipine Market By Type 2022-2034 (USD MILLION/ Units)
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
      2. LATAM Nifedipine Market By Application 2022-2034 (USD MILLION/ Units)
        1. Primary Pulmonary Hypertension
        2. Heart Failure
        3. Raynaud’s Syndrome
        4. Cephalalgia
        5. Others
      3. LATAM Nifedipine Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Others
      4. LATAM Nifedipine Market By Region 2022-2034 (USD MILLION/ Units)
        1. North America
        2. Asia-Pacific
        3. Europe
        4. Latin America
        5. The Middle East and Africa
      5. Brazil
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      6. Mexico
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      7. Argentina
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      8. Chile
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      9. Colombia
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
      10. Rest of LATAM
        1. Nifedipine Controlled-Release Tablets
        2. Nifedipine Extended Action Tablets
        3. Primary Pulmonary Hypertension
        4. Heart Failure
        5. Raynaud’s Syndrome
        6. Cephalalgia
        7. Others
        8. Hospital Pharmacies
        9. Retail Pharmacies
        10. Others
        11. North America
        12. Asia-Pacific
        13. Europe
        14. Latin America
        15. The Middle East and Africa
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.